Table 1 Demographic and clinical characteristics of controls and PMP patients included.
Non-tumor | Tumor | ||
|---|---|---|---|
Low grade | High grade | ||
Patients, [n] | 11 | 10 | 8 |
Age, [median (IQR)] | 53 (28-68) | 62.5 (48-76) | 60 (48-71) |
Women, (%) | 45.5 | 60 | 50 |
Adjuvant treatment, (%) | – | 20 | 37.5 |
Morbidity, [Clavien–Dindo 1-5 (%)] | – | 1: 30 | 1: 25 |
– | 2-5: 70 | 2-5: 75 | |
Elevated CEA, (%) | – | 55.6 | 12.5 |
Elevated CA9.9, (%) | – | 22.2 | 12.5 |
Elevated CA125, (%) | – | 33.3 | 14.3 |
Peritoneal Cancer Index, [median (IQR)] | – | 31 (23-39) | 22 (13-39) |
Residual Disease, completeness of cytoreduction (CC), (%) | – | CC0-CC1: 80 | CC0-CC1: 75 |
– | CC2-CC3: 20 | CC2-CC3: 25 | |
Ki67, [median (IQR)] | – | 15 (10-22.5) | 30 (15-50) |
Recurrence, (%) | – | 22.2 | 12.5 |
Months of Relapse-Free Survival, [median (IQR)] | – | 26 (21.5-28.5) | 14 (11-18) |
Death, (%) | – | 20 | 28.6 |
Months of Overall Survival, [median (IQR)] | – | 23 (21.25-28) | 15 (9.5-19) |
